Skip to playerSkip to main content
  • 9 minutes ago
A significant real-world study presented at the European Respiratory Society Congress in Barcelona highlighted that semaglutide, the active ingredient in Ozempic and Wegovy, is associated with almost a 40% reduction in asthma attacks and approximately a 20% decrease in flare-ups of COPD. Conducted by Professor Chloe Bloom from the National Heart and Lung Institute at Imperial College London, the research analyzed UK medical records across four concurrent studies, each involving 20,000 to 22,000 individuals who initiated GLP-1 therapies compared to those on other diabetes medications. The findings suggest that GLP-1 medications may provide respiratory advantages in addition to their benefits for diabetes and obesity, although further clinical trials are necessary to validate these results.
Disclosure:
This video contains stock footage and content created or enhanced using AI-assisted tools.

ai-generated

Category

🗞
News
Transcript
00:00A popular weight loss and diabetes drug might be doing something nobody expected for people with
00:05asthma. Simaglutide, the active ingredient in Ozempic and Wagovi, was linked to nearly 40%
00:11fewer asthma attacks in a large real-world study presented at the European Respiratory Society
00:17Congress in Barcelona. It was also associated with about 20% fewer COPD flare-ups. The research,
00:24led by Professor Chloe Bloom at Imperial College London, used UK medical records to
00:29run four parallel studies, each following between 20,000 and 22,000 people who started GLP-1
00:36treatments compared to those on other diabetes medicines. Researchers believe the anti-inflammatory
00:42effects of GLP-1 drugs may be behind the benefit, extending well beyond their known effects on
00:47blood sugar and weight. Experts caution that clinical trials are still needed, and people
00:52shouldn't try to self-prescribe for these benefits. Disclosure. This video contains stock footage and
00:57content created or enhanced using AI-assisted tools.
Comments

Recommended